Últimas investigaciones científicas sobre cáncer colorrectal
Copia esta URL y pégala en tu lector RSS favorito (Feedly, Inoreader, etc.)
https://crcwarriors.org/api/scientific-news.php?action=rss
Mitochondrial dysfunction is a pivotal pathogenic mechanism in colorectal cancer (CRC), which is further exacerbated by dysregulated liquid-liquid phase separation (LLPS). However, the mechanisms underlying mitochondrial dysfunction and LLPS, as well as their therapeutic targeting, remain unclear. U...
Although hyperthermic intraperitoneal chemotherapy (HIPEC) added to cytoreductive surgery shows promise for colorectal cancer with peritoneal metastases (CRC-PM), effectiveness remains variable. Given the predominance of consensus molecular subtype 4 (CMS4) in CRC-PM and resistance to standard agent...
The relationship between inflammation and tumorigenesis has been widely investigated, with tumor-promoting inflammation proposed as an "enabling characteristic." However, little is known about the prognostic value of surgery-related inflammation. This study evaluates whether postoperative inflammati...
Conventional in vitro models often inadequately replicate the intricate vascular networks of tumors, limiting their translational relevance. Recent advances in vascularized tumor organoids offer a transformative approach to modeling angiogenic mechanisms and tumor microenvironment (TME) dynamics wit...
Tumor mutational burden (TMB) is a predictive biomarker for immune checkpoint inhibitors (ICIs). Its clinical utility in head and neck squamous cell carcinoma (HNSCC) is limited by differences in detection approaches and inconsistent cut-off values. In this meta-analysis, we systematically reviewed ...
Microsatellite stable and mismatch repair proficient colorectal cancer (CRC) represents the largest population of patients exposed to immune checkpoint inhibitors, yet remains largely refractory to these therapies. Resistance is commonly attributed to low tumor mutational burden or limited neoantige...
The vitamin D receptor (VDR) is a key regulator of cellular growth and differentiation, and accumulating evidence links vitamin D signaling to tumor biology. However, the specific contributions of VDR across diverse cancers remain incompletely understood. This narrative review synthesizes current kn...
Colorectal cancer (CRC) is a common malignancy of the colonic and rectal epithelia. Numerous patients with CRC derive only limited and unsustained benefit from conventional chemotherapy or immunotherapy, underscoring the need for novel treatments. Ferroptosis is an iron‑dependent, lipid peroxidati...
Completion total mesorectal excision (cTME) after local excision of early rectal cancer is associated with substantial morbidity and impaired functional outcomes. This study aimed to assess the oncological outcomes of adjuvant chemoradiotherapy as an organ-preserving alternative in patients with hig...
Immune checkpoint inhibitors elicit responses in merely 20-40% of patients with microsatellite instability-high or mismatch repair-deficient colorectal cancer (CRC), making immunotherapy resistance a formidable clinical challenge. The immunosuppressive tumor microenvironment, characterized by regula...
BRAFV600E-mutant colorectal cancer (CRC) represents an aggressive molecular subtype characterized by poor prognosis and resistance to standard therapies. Predictive models to guide treatment selection and overcome drug resistance are urgently needed. We established a biobank of patient-derived organ...
Liquid biopsy has become an increasingly important tool in clinical oncology due to the utility of circulating tumor DNA (ct-DNA). Plasma ct-DNA levels reflect the tumor burden of patients and provide valuable information for personalized treatment strategies. Colorectal cancer (CRC) is among the mo...
Peptide-drug conjugates (PDCs) represent a targeted cancer therapy strategy that combines tumor-homing peptides with potent cytotoxic payloads, offering a promising alternative to antibody-drug conjugates (ADCs) through improved tissue penetration, synthetic accessibility, and tumor selectivity. Aur...
Image-guided thermal ablation (IGTA) is a minimally invasive alternative to colorectal cancer lung metastases (CRLM) for non-surgical candidates. This study evaluated whether combined RAS/SMAD4 mutational status and microsatellite instability (MSI) predict outcomes after IGTA in CRLM, addressing the...
Sessile serrated lesions with dysplasia (SSLd) are direct precursors of colorectal carcinomas (CRCs) but pose a diagnostic challenge. We aim to explore contemporary practice leading to recommendations to improve detection of dysplasia. (i) The frequency of dysplasia in SSLs was estimated through a n...
The metabolic differences between tumor cells and normal tissue cells offer potential targets for therapeutic intervention. For instance, compared to normal tissues, tumor cells exhibit a significantly higher dependency on methionine. However, current strategies for methionine restriction have limit...
Cuproptosis represents a promising avenue for cancer immunotherapy, yet its efficacy is limited by difficulties in achieving targeted mitochondrial copper ion accumulation and upregulating cells reliance on mitochondrial respiration. To address this, we develop a biomimetic copper-based nanoplatform...
Early exposure to checkpoint blockade restores immune-sensitivity in localized, immune-excluded cancers. In this issue of Med, Zhang et al. reported promising pathological activity of 3-month preoperative cadonilimab (bispecific anti-PD-1/CTLA-4 antibody) with modified FOLFOXIRI triplet intensive ch...
Immune checkpoint inhibitors (ICI) are standard for MSI-H/dMMR metastatic colorectal cancer (mCRC). We compared their efficacy and sought subgroups deriving greater benefit from ICI combination. All patients with MSI/dMMR mCRC treated by anti-PD-1 ± anti-CTLA-4 in the prospective monocenter immunoM...
Immune checkpoint inhibitors (ICI) provide durable responses in a subset of colorectal cancers, yet benefit is largely confined to microsatellite instability-high (MSI-H) tumors. We investigated whether the tumor-penetrating peptide iRGD enhances anti-programmed cell death protein 1 (PD-1) treatment...
Tumour agnostic therapies represent a paradigm shift in oncology. BRAF inhibitors have demonstrated efficacy in melanoma. However, their role in non-melanomatous cancers was originally contentious. This systematic review aims to evaluate the safety and efficacy of BRAF-targeted therapies, both as mo...
Colorectal cancer (CRC) is the leading cause of cancer-related morbidity and mortality attributable to cancer worldwide. Therefore, there is still a need for strong biomarkers that can be used to assist with the diagnosis, prognostication, and therapeutic stratification of patients. The role of auto...
The worldwide impact of colorectal cancer (CRC) as a primary cause of cancer-related morbidity and mortality demonstrates the urgent need for better early detection methods and personalized treatment approaches. While colonoscopy and fecal tests have contributed to reduced mortality rates from CRC, ...
ABO blood group antigens influence cell adhesion, inflammation, and metastatic processes, raising interest in their potential prognostic role in colorectal cancer. However, previous studies have reported inconsistent findings. This study evaluated the association between ABO blood group and overall ...
In colorectal cancer (CRC), tumor-infiltrating regulatory T (Treg) cells suppress anti-tumor immunity, promoting immune evasion and tumor progression. Effective therapies require selectively targeting tumor-infiltrating Treg (TI-Treg) cells while preserving systemic Treg cells, necessitating insight...
Despite the clinical relevance of KRASG12V in colorectal cancer, KRASG12V-specific inhibitors remain limited. Through structure-based virtual screening of a 59,319-member peptide library, we identified four KRASG12V-targeting peptides, among which Peptide-1 showed the most favourable docking profile...
Early-onset colorectal cancer (EOCRC) is increasing globally and exhibits both aggressive clinicopathological features and distinct molecular characteristics. However, the relative contribution of clinical and genetic factors to prognosis remains unclear, particularly in underrepresented populations...
Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) are highly mutated and immunogenic yet frequently escape immune elimination. To define how host immunity shapes the genomic architecture and tumour microenvironment of MMRd CRC. We used a genetically engineered mouse model of MMRd CRC to com...
In traditional Chinese medicine (TCM), colorectal cancer (CRC) is commonly associated with patterns such as damp-heat accumulation, heat toxin, and yin deficiency. Sanwu Huangqin Decoction (SWHQD) is a classical traditional Chinese medicine (TCM) formula composed of three medicinal herbs-Huangqin (S...
Efforts to improve outcomes for patients with metastatic colorectal cancer (mCRC) treated with bevacizumab are limited by the lack of validated predictive biomarkers. To overcome this challenge, our study prospectively assessed the combined prognostic and predictive significance of circulating angio...
Locally advanced rectal cancer is commonly treated using total neoadjuvant therapy (TNT), which integrates radiotherapy with systemic chemotherapy to improve tumor downstaging, local control, and long-term oncologic outcomes. Despite its central role in treatment, responses to radiotherapy remain hi...
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerizat...
Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. A consistent and epidemiologically well-documented feature of CRC is its sexual dimorphism: age-standardized incidence rates are 33-45% higher in men than in women, and ...
Molecular imaging of tumor biomarkers represents a crucial direction for advancing precision cancer diagnosis and therapy. As a core regulator of tumor angiogenesis, VEGFR2 represents an ideal molecular imaging target. Herein, a novel VEGFR2-targeting peptide (HTMYYHHYQHHLSSSDICLPRWGCLWED, named as ...
The precise activation of the cGAS-STING pathway for effective tumor immunotherapy remains a significant challenge due to the complexity of immune responses and tumor microenvironment (TME) limitations. Here, a multifunctional nanoagonist, cRGD-PDA/ZIF8@ICG/TPT (cDZ@IP), was developed to realize nan...
Characterizing the tumor immune microenvironment (TIME) is essential for understanding anti-tumoral responses in colon cancer. This study introduces TIME Landscaper (TIMEL), a computational framework that uses deep learning to identify tissue structures at the microscopic level and summarizes their ...
Targeted therapies have broadened the treatment landscape for colorectal cancer (CRC), highlighting the need for rational combination strategies. Although sorafenib and GW5074 show therapeutic promise and lidocaine may sensitise cancer cells to treatment, the mechanisms underlying these combinations...
Despite advances in treatment, brain metastasis (BM) management remains a significant challenge. Adagrasib is a brain-penetrant KRASG12C inhibitor active in patients with BM. KRAS mutations are linked with immune escape and may contribute to the limited clinical benefit from single-agent immune chec...
Hydrogen (H2), a non-toxic therapeutic gas, exerts antitumor effects by disrupting intracellular redox homeostasis and inducing mitochondrial dysfunction. The high diffusibility of H2, as well as its storage difficulties, hinders its sustained release at tumor sites. Thus, the therapeutic effect rem...
Biomarkers, particularly prognostic and immune based, are lacking in colorectal cancer (CRC). This study aimed to evaluate the expression of novel immune based biomarkers among patients with CRC to predict clinical outcomes. A CRC tumor microarray (TMA) was developed from a multiracial patient popul...
Mismatch repair deficiency (dMMR)/Microsatellite instability (MSI) plays a central role in colorectal cancer (CRC) as a predictive and prognostic biomarker and as a "red flag" for diagnosis of Lynch Syndrome (LS). HER2 is emerging as a therapeutic target and clinical trials are ongoing. Several repo...
Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with tr...
This literature-based systematic review and associated guidelines provide evidence-based paradigms for the management of locoregionally recurrent rectal cancer (LRRC). This multispecialty committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and colorectal ...
The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer (mCRC). However, its safety and efficacy in patients with significant liver dysfunct...
Treatment of colorectal cancer has fundamentally evolved due to molecular characterization and biomarker-driven strategies. To summarize key personalized treatment approaches in colorectal cancer with a focus on clinically relevant molecular subgroups. Molecular biomarkers increasingly guide treatm...
Mutations in the KRAS gene are some of the most frequent drivers in cancer, including non-small cell lung and colorectal cancer. Covalent inhibitors such as adagrasib, targeting the inactive, GDP-bound form of KRAS-G12C, have shown clinical efficacy but patient selection still depends on invasive bi...
Fluoropyrimidine regimens in gastrointestinal oncology have evolved empirically. Bolus 5-fluorouracil (5-FU)-containing combinations now coexist with continuous metronomic schedules and oral prodrugs, while immune checkpoint inhibitors (ICIs) seek chemotherapy partners for microsatellite-stable (MSS...
The clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C) that was steadily expressed i...
Primary tumor sidedness is a major determinant of biologic-agent selection in RAS/BRAF wild-type metastatic colorectal cancer (mCRC), but it remains an anatomic surrogate rather than a mechanistic biomarker. Genome-wide DNA methylation status has emerged as a biologically informative classifier that...